碧迪医疗股价上涨4.72%，财报超预期与分析师上调目标价提振市场信心

Company Performance - The company reported Q4 2025 revenue of $5.89 billion, an 8% year-over-year increase, with adjusted earnings per share of $3.96, exceeding Wall Street's average expectations [2] - For the full fiscal year, revenue reached $21.84 billion, reflecting an 8.2% year-over-year growth, indicating continuous improvement in profitability [2] - The life sciences segment showed signs of recovery, while the diagnostics solutions business returned to positive growth during the quarter [2] Analyst Ratings - Between February 10 and 11, 2026, multiple institutions updated their ratings, with TD Cowen raising the target price from $183 to $189 while maintaining a "Hold" rating [3] - Citigroup maintained a "Buy" rating with a target price of $232, which is among the higher forecasts from analysts [3] - Market sentiment is focused on the company's strategic shift following the sale of its life sciences business [3] Industry Environment - The medical device sector has recently been catalyzed by policy changes and innovation themes [4] - On February 10, 2026, the China International Medical Equipment and Devices Trading Platform was launched, enhancing global expectations for the industry [4] - The company reported a robust cash flow, with free cash flow for fiscal year 2025 amounting to $2.67 billion, supporting dividend payments [4]